How do other banks ER teams survive?
I’ve been making a spreadsheet of all the banks on biotech IPOs, PIPEs, and follow-on deals, and it’s legit the same banks that take like 95% of the deals. So my question is: how the heck are these other banks biotech Analysts still around given they’re not bringing in fees? Biotech analysts aren’t exactly cheap so how are they around if their research doesn’t translate into deal fees through equity offerings, etc?
Biotech banking syndicates usually involve the usual: Jefferies, Leerink, JPM, Piper, LifeSci, and Guggenheim. I see these banks consistently on deals, of course others exist but seem to be much less so. With the sheer volume of biotech equity deals just in the first 3 months of the year, are these guys absolutely crushing it? Is biotech a different world than other sectors? And seriously, should I go get a biotech masters and lateral to a biotech team from TMT??
who is LifeSci Capital and how are they on all these deals? Didn’t know about em and just looked it up. Good bank to join if they’re up and coming in biotech?
Also, Leerink is murdering this year for biotech holy hell.
Amet sapiente consectetur consequatur voluptas magni dolores ea. Aut voluptatem et quae esse error rerum odit voluptas. Rerum repudiandae voluptatem nostrum adipisci.
Cum qui nemo aliquam ea. Dignissimos voluptatem tempore at excepturi harum animi porro. Voluptatem et qui aut debitis est. Sequi quis reiciendis repellat dolorem corporis et doloribus. Error recusandae nihil qui rerum ut nisi et.
Atque ea qui voluptas et. Omnis voluptatem provident nisi non a.
Accusamus sequi quo fugiat et. Voluptates aliquid aliquam voluptate saepe quae animi. Pariatur et autem autem velit praesentium in consequatur. Asperiores ut omnis fuga sequi adipisci veniam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...